Teplizumab is an immunotherapy drug designed to modify the immune system's response. Instead of simply treating symptoms, it ...

The immunotherpay can give children and adults three extra years before they need to use insulin.

It’s a development millions of people living with Type 1 diabetes never thought would happen. A new study is showing promising a functional cure for the life-long disease.

Type 1 diabetes is an autoimmune disease in which the immune system attacks the insulin-producing beta cells of the pancreas.

Teplizumab is used to delay the onset of stage 3 type 1 diabetes in children aged 8 years and older, and adults, with stage 2 ...

Type 1 diabetes (T1D) is commonly diagnosed in childhood and the teen years. It’s a lifelong condition that requires treatment. Type 1 diabetes (T1D) is an autoimmune disease that occurs when the ...

A disease modifying therapy that can delay the onset of type 1 diabetes for up to three years has been recommended for use on ...

There’s a cliché in the type 1 diabetes community that a cure has been “five years away” for as long as anyone can remember. For decades, patients have been told that researchers were on the verge of ...

Once known as “juvenile” diabetes, type 1 diabetes was long considered a childhood disease. Although the condition is often diagnosed in children and teenagers, it can develop at any age. Type 1 ...

As of 2022-2023 data in Denmark, influenza vaccination coverage in patients with T1D remained below the World Health Organization target of 75%, reaching only 16.9% in children and 41.8% in adults.

In a landmark announcement, the NHS has introduced a beacon of hope for individuals susceptible to type 1 diabetes.